Surfactant Replacement in Neonates with Respiratory...

Surfactant Replacement in Neonates with Respiratory Distress Syndrome Type The innovation of surfactant replacement therapy in the treatment of respiratory distress syndrome has proven to increase the survival and minimize the complications of the premature neonate. Replacing surfactant has lessened time on ventilators, and allowing the neonate and parents an opportunity to grow together earlier outside of intensive care. This paper will discuss the etiology of respiratory distress syndrome type I, the treatment options and nursing care of the neonate during surfactant replacement. Respiratory distress syndrome type I is a decrease production of surfactant, a noncelluar chemical produced in the type II alveolar in the lungs†¦show more content†¦These include maternal hypertension, gestational diabetes excluding classes D, F, and R, intrauterine growth restriction, preterm labor, and drug abuse. The neonate high risk factors are birth prior to 32 weeks, weighing less then 1300 grams and laboratory data suggesting poor lung maturity discussed later. (Bower, Barnhart, betiti, Hendon, Masi-lynch, Wilson, 825) The highest risk factor for RDS type I is an insulin dependent diabetic mother, because boluses of insulin injections severely decrease the fetus production of surfactant. (Porth, 1306)) Chronic hypoxic events during pregnancy associated with mild to moderate maternal hypertension have shown however to sometime accelerate fetal lung maturity and surfactant production leading to a decrease in neonatal respiratory complications. (Kim, Vohr, Oh, 39) This due to cortical steroid secretion that stimulate an increased production of surfactant in response to the stresses of hypoxic events. (Porth, 1306) The symptoms of oncoming RDS may at first not be present in a fetus greater then 28 weeks since they have produced enough surfactant to thrive outside of uterine life for a short time. However the high initial pressure to breathe the first breath remains constant with each subsequent breath causing extreme effort forShow MoreRelatedSurfactant Replacement Therapy And The Affects On Rds And Other Pulmonary Disorders2631 Words   |  11 Pages Surfactant Replacement Therapy and the Affects on RDS and Other Pulmonary Disorders Jacquelyn M. Wood Grossmont Community College 2015 INTRODUCTION As a newborn makes their entrance to this world from intrauterine life all should go smoothly. The newborn is delivered and is stimulated to breathe and then is followed by inspirations, followed by a cry showing a successful arrival to this world, but not all deliveries go as planned. There are diseases of the respiratory systemRead MoreSymptoms And Treatment Of Congenital Pulmonary Alveolar Proteinases ( Pap )997 Words   |  4 Pageswith surfactant mutations, which could provide future novel methods for diagnosis and therapeutic purposes (Robin R. et al 2010). Treatment The first successful study, demonstrating the effectiveness of natural lung surfactant administration in a young rabbit model of respiratory distress syndrome (RDS) was carried out by G. Echoing and Robertson in 1972, later, the first report of the first report of the important clinical utilization of surfactant therapy in neonates with the respiratory distressRead MoreSymptoms And Treatment Of Respiratory Distress Syndrome1364 Words   |  6 PagesRespiratory distress is common, affecting up to 70% of all premature newborns, and is increasingly common in even modest prematurity. Preventive and therapeutic measures for some of the most common underlying causes are well studied and when implemented can reduce the burden of disease. Failure to readily recognize symptoms and treat the underlying cause of respiratory distress in the newborn can lead to short- and long-term complications, including chronic lung disease, respiratory failure, andRead MoreRespiratory Distress Syndrome Essay 1807 Words   |  8 PagesRespiratory distress syndrome (RDS), also known as hyaline membrane disease (HMD), is a disease that predominantly affects premature neonates. It is due to a deficiency in surfactant which is vital in increasing lung compliance, preventing atelectasis at the end of expiration, and promoting the recruitment of collapsed alveoli by reducing surface tension. Its other name, HMD, is derived from the characteristic histological findings in early post mortems of premature babies, hyaline membranes wereRead MoreSymptoms And Treatment Of Infant Respiratory Distress Syndrome2314 Words   |  10 Pagesoccur with child birth. â€Å"Approximately 50% of neonates born at 26-28 weeks gestation develop respiratory distress syndrome, whereas less than 30% of premature neonates born at 30-31 weeks’ gestation develop the condition† (MedScape). Infant Respiratory Distress Syndrome, or IRDS for short, is a restrictive lung disease that commonly occurs in premature babies. A common cause is a lack of surfactant that is commonly found in developed lungs. Surfactant is a liquid that uses proteins and lipids toRead MoreSymptoms And Symptoms Of Neonatal Respiratory Distress Syndrome4658 Words   |  19 PagesIntroduction II. Continuous Positive Airway Pressure (CPAP) a. History b. Physiological Effects c. Types of CPAP Delivery Devices i. Nasal Masks ii. Nasal Prongs iii. Nasopharyngeal Prongs III. Bubble CPAP System a. Understanding How it Works i. System Setup ii. Nebulization of Drugs iii. Cost iv. Difficulty of Use IV. Indications for Bubble CPAP in Neonatal Patient a. Neonatal Respiratory Distress Syndrome (RDS) i. Definition of Neonatal RDS ii. Characteristics of RDS in Different Gestational Ages 1Read MoreNeonatal Respiratory distress syndrome reflective practice Essay5076 Words   |  21 Pagescaring for a sick neonate with Respiratory Distress Syndrome (RDS) in the neonatal unit. This has enabled me to explore the meaning and significance of my clinical practice and to recognise the complexities within it. The experience raises a number of issues frequently encountered in daily nursing practice. Within this assignment, I will be discussing a particular pre term baby with RDS and critically analyse the use of nasal continuous positive airways pressure (NCPAP) and surfactant therapy and possible